IRIS
QUINTARELLI, CONCETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.946
AS - Asia 3.149
EU - Europa 2.523
SA - Sud America 362
Continente sconosciuto - Info sul continente non disponibili 174
AF - Africa 94
OC - Oceania 3
Totale 10.251
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.709
SG - Singapore 1.427
RU - Federazione Russa 977
IT - Italia 673
CN - Cina 538
VN - Vietnam 485
HK - Hong Kong 328
BR - Brasile 296
DE - Germania 141
CA - Canada 132
FR - Francia 127
FI - Finlandia 112
UA - Ucraina 106
GB - Regno Unito 91
IE - Irlanda 83
JP - Giappone 75
NL - Olanda 75
BD - Bangladesh 69
IN - India 56
SE - Svezia 30
ES - Italia 26
PL - Polonia 26
MX - Messico 24
ZA - Sudafrica 23
KR - Corea 21
AR - Argentina 20
PH - Filippine 18
IQ - Iraq 17
GT - Guatemala 16
SC - Seychelles 16
ID - Indonesia 15
JM - Giamaica 14
LT - Lituania 13
EC - Ecuador 12
EG - Egitto 11
TH - Thailandia 11
TR - Turchia 11
UZ - Uzbekistan 10
CI - Costa d'Avorio 9
CO - Colombia 9
CR - Costa Rica 9
IL - Israele 9
AT - Austria 8
CL - Cile 8
PK - Pakistan 8
TT - Trinidad e Tobago 8
AE - Emirati Arabi Uniti 7
MA - Marocco 7
SV - El Salvador 7
CW - ???statistics.table.value.countryCode.CW??? 6
ET - Etiopia 6
LV - Lettonia 6
TW - Taiwan 6
VE - Venezuela 6
HN - Honduras 5
SA - Arabia Saudita 5
BE - Belgio 4
BO - Bolivia 4
DZ - Algeria 4
HR - Croazia 4
NI - Nicaragua 4
PR - Porto Rico 4
PY - Paraguay 4
BW - Botswana 3
CH - Svizzera 3
EE - Estonia 3
GE - Georgia 3
HU - Ungheria 3
IR - Iran 3
JO - Giordania 3
KW - Kuwait 3
KZ - Kazakistan 3
MK - Macedonia 3
MY - Malesia 3
SN - Senegal 3
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
BS - Bahamas 2
DM - Dominica 2
EU - Europa 2
GP - Guadalupe 2
LA - Repubblica Popolare Democratica del Laos 2
ML - Mali 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
RO - Romania 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CU - Cuba 1
CY - Cipro 1
Totale 10.067
Salva come PNG Salva come JPEG
Città #
Singapore 649
San Jose 535
Ashburn 457
Hong Kong 319
Council Bluffs 270
Moscow 222
Chandler 198
Beijing 147
Santa Clara 119
Ho Chi Minh City 114
Hanoi 105
Millbury 87
Los Angeles 82
Lauterbourg 75
Rome 70
The Dalles 70
Tokyo 65
Hefei 64
Napoli 61
Munich 60
Amsterdam 58
Buffalo 57
Naples 51
Dong Ket 48
New York 47
Princeton 47
São Paulo 47
Milan 42
Nanjing 40
Dallas 39
Turku 34
Boston 33
Des Moines 33
Frisco 32
Phoenix 32
Redondo Beach 32
Toronto 32
Brooklyn 31
Jacksonville 30
North Bergen 30
Wilmington 26
Montreal 25
Orem 25
Lawrence 24
Atlanta 23
Frankfurt am Main 22
Helsinki 22
Chennai 21
Dublin 21
London 21
Ottawa 21
Chicago 20
Da Nang 19
Warsaw 19
Haiphong 18
San Francisco 18
Seattle 17
Denver 16
Turin 15
Johannesburg 13
Nuremberg 13
Poplar 13
Guatemala City 12
Houston 12
Falkenstein 11
Falls Church 11
Brasília 10
Jiaxing 10
Kingston 10
Mexico City 10
Miami 10
Rio de Janeiro 10
Seoul 10
Brescia 9
Charlotte 9
Fairfield 9
Lappeenranta 9
Mumbai 9
Nanchang 9
Shenyang 9
Tianjin 9
Chongqing 8
Raleigh 8
Redwood City 8
Tashkent 8
Biên Hòa 7
Changsha 7
Florence 7
Guangzhou 7
Guidonia 7
Madrid 7
San Salvador 7
Stockholm 7
Augusta 6
Cambridge 6
Ninh Bình 6
Palermo 6
Philadelphia 6
Quận Ba 6
Riga 6
Totale 5.314
Salva come PNG Salva come JPEG
Nome #
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 479
NANOG: ITS ROLE IN THE TKI RESISTANCE OBSERVED IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA 259
Transition index: new original tool to identify subsets overlapping MPN phenotypes. 212
SPLEEN VOLUME IS THE MOST ACCURATE PARAMETER TO AVOID UNDERSTIMATION OF 25% SPLENOMEGALIC PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 192
Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies 188
Advanced-stage Hodgkin Lymphoma: US/Chest Radiography for Detection of Relapse in Patients in First Complete Remission—A Randomized Trial of Routine Surveillance Imaging Procedures 186
Spleen is the dark side of essential Thrombocitemia 186
A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia 181
UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA 170
B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies 166
MOLECULAR EVALUATION OF ZNF224 MRNA EXPRESSION IN CML PATIENTS AS A NOVEL DETERMINANT OF TKI RESPONSIVENESS 163
Adoptive immunotherapy using prame-specific t cells in medulloblastoma 159
WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene 151
Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation 149
SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best 148
L'ATTIVITÀ DEGLI INIBITORI DI TIROSINA KINASI (TKI) SULLA PROLIFERAZIONE E L'ATTIVAZIONE DELLE CELLULE T 147
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells 142
Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib. 141
CLINICAL RELEVANCE IN CHRONIC MYELOID LEUKEMIA OF DELETION AND INSERTION EVENTS IN THE TYROSINE KYNASE DOMAIN OF BCR-ABL 139
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. 137
PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism 137
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical relation. 134
Cytotoxic T lymphocytes directed to the Preferentially Expressed Antigen of Melanoma (PRAME) target chronic myeloid leukemia. 134
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia 126
Preferentially expressed antigen of melanoma (PRAME)-specific cytotoxic T-Lymphocytes (CTLs) and transgenic T cells to target chronic myelogenous leukemia (CML) 123
Molecular monitoring in chronic myeloid leukemia (CML) 123
Decitabine up-regulates the expression of the cancer-associate prame antigen in early chronic phase CML cells. 121
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. 121
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma 121
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma 119
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model 117
Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing 117
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. 116
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients 113
The biological resources and molecule archives organization: Turn a need into an opportunity for the Smart Specialization Strategy of the Lazio region 112
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells 110
Allogeneic CAR T cells: A new player in the field and the peculiar opportunities of the hospital exemption path 106
Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring 106
A small animal in vivo imaging model of expanded vs. unexpanded UCB stem cells reveals differential patterns of engraftment 105
Gene therapy to improve function of T cells for adoptive immunotherapy. 104
Co-Expression of a Chimeric Antigen Receptor Targeting CD19 (CAR19), Optimized Human IL-15, and iCaspase9 To Enhance the Activity and Safety of Cytotoxic T Lymphocytes 104
Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. 103
Early detection of residual disease by Q-RT-PCR of the hybrid BCR/ABL transcript is a powerful predictor of treatment response in adult Philadelphia - Positive acute lymphoblastic leukemia. 103
Overcoming challenges in CAR T-cell product CGMP release 102
Gene transfer of IL-7R alpha (IL-7R alpha) on antigen-specific cytotoxic T cells (CTLs) restores their ability to respond to IL-7 cytokine 101
Generation of Epstein Barr Virus Specific Cytotoxic T Lymphocytes (EBV-CTLs) Resistant to the Immunosuppressive Drug Tacrolimus (FK506) 101
CLINICAL OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH DELETION AND INSERTION EVENTS (DI) IN THE TYROSINE KINASE DOMAIN OF BCR-ABL 100
Transgenic expression of inducible caspase9 suicide gene for in vivo elimination of antigen specific cytotoxic T cells (CTLs) engineered to produce cytokines. 97
Induction of PRAME-specific immunity by overlapping pentadecapeptides in patients with hematologic malignancies 97
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells 96
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring 95
Ethics-aware data governance (Vision Paper) 94
Hepatitis B virus reactivation after fludarabine-based regiments for indolent non-Hodgkin’s lymphomas: high prevalence of acquired viral genomic mutations. 93
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. 92
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. 92
Stimuli-responsive nanoparticle-assisted immunotherapy: A new weapon against solid tumours 92
Generation of EBV specific cytotoxic T lymphocytes (EBV-CTLs) resistant to the immunosuppressive drug FK506 91
Polyclonal PRAME-Specific Cytotoxic T Lymphocytes Generated Using Protein-Spanning Pools of Overlapping Pentadecapeptides Target Chronic Myeloid Leukemia 90
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks 89
Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔCD19 89
Engineering CD19-Redirected T Lymphocytes to Enhance Their Safety and Efficacy 88
Transgenic expression of IL15 selectively expands antigen specific cytotoxic T cells (CTLs) enhancing their anti-tumor effect in vivo. 87
Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9 84
Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma 82
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). 80
Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse 76
Autologous CD19-Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis 75
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7 75
A novel MLL/AF4 fusion gene lacking the AF4 transactivating domain in infant acute lymphoblastic leukemia. 73
Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy 72
Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients 72
The immune system of children: the key to understanding SARS-CoV-2 susceptibility? 72
NK Cell-Based Immunotherapy for Hematological Malignancies 69
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia 66
Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study 65
Preservation of antigen-specific functions of αβ T cells and B cells removed from hematopoietic stem cell transplants suggests their use as an alternative cell source for advanced manipulation and adoptive immunotherapy 64
MicroRNAs in neuroblastoma: Biomarkers with therapeutic potential 64
Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia 62
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial 61
Generation and expansion of PRAME-specific cytotoxic T-lymphocytes for adoptive T-cell therapy of hematological malignancies. 59
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. 57
Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells 54
The EURE-CART project as a prototype model for CAR T-cell immunotherapy in Europe 52
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis 50
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases 29
A biodegradable hydrogel based on carboxymethyl cellulose/silver nanoparticles for wound closures 23
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? 20
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting 20
PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches 18
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors 18
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma 17
SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity 17
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma 17
Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters 16
GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango? 16
The immune response as a double-edged sword: The lesson learnt during the COVID-19 pandemic 16
GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system 15
Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We? 15
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles 15
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 14
Totale 9.926
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.213
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.213
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022445 0 0 0 0 5 17 7 17 82 23 130 164
2022/2023511 73 32 20 10 65 57 8 67 92 47 24 16
2023/2024309 17 51 46 23 15 25 6 23 10 9 64 20
2024/20252.223 101 155 9 26 59 100 224 147 128 222 751 301
2025/20264.438 482 303 435 442 718 162 479 248 434 359 244 132
2026/20271.441 171 295 206 720 49 0 0 0 0 0 0 0
Totale 10.251